Reifenstein syndrome is a form of partial androgen insensitivity syndrome (PAIS), a condition in which a person with XY chromosomes produces androgens normally but their body cannot respond to those hormones fully because of a defect in the androgen receptor. The name comes from a 1947 clinical report describing families of undervirilized males with a shared pattern of genital differences, breast tissue growth, and reduced fertility. Today most clinicians prefer the broader term “partial androgen insensitivity syndrome,” since the underlying problem is not unique to one family or one mutation but reflects a spectrum of defective androgen action.
Why the Name Still Appears and What It Actually Means
Edward Reifenstein originally described a hereditary pattern in which affected males had a small penis, an abnormal urethral opening (hypospadias), prominent breast development (gynecomastia), and low sperm counts, yet their testes produced hormones at apparently normal levels. For decades the condition was grouped loosely with other forms of “male pseudohermaphroditism,” a term now considered outdated and inaccurate. A landmark 1977 study of eight patients confirmed that the hormonal machinery was intact: plasma androgen levels were normal or even elevated, testosterone and dihydrotestosterone production rates were normal, and the enzyme that converts testosterone to its more potent form in skin was working fine. The problem, that study concluded, lay in the cell’s ability to act on those androgens, making “partial androgen insensitivity syndrome” a far more precise label than any name tied to a single clinical description.1PubMed. Partial androgen insensitivity: the Reifenstein syndrome revisited
You will still encounter “Reifenstein syndrome” in older medical literature, patient-facing resources, and some genetic databases. It refers to a specific slice of the PAIS spectrum, typically 46,XY individuals raised male who have perineal or penile hypospadias, gynecomastia that appears at puberty, and some degree of infertility. The term is not wrong per se, but it can give the misleading impression that this is a single, uniform condition rather than a variable outcome of many possible androgen receptor mutations.
The Genetic Root of the Problem
Reifenstein syndrome traces back to mutations in the androgen receptor (AR) gene, which sits on the X chromosome. Because XY individuals carry only one copy of that chromosome, a single mutation is enough to affect receptor function throughout the body. The mutations themselves vary widely from family to family, which is one reason the clinical picture can look so different from one person to the next.
Some mutations hit the part of the receptor that binds to DNA inside the cell nucleus. In two families studied through gene sequencing, researchers found the same single-letter change in the DNA-binding domain: a guanine-to-adenine switch that swapped one amino acid for another right next to a critical structural feature of the receptor. When that mutant receptor was tested in laboratory cells, its ability to turn on androgen-responsive genes dropped by roughly two-thirds compared to the normal version.2PubMed Central. Point mutation in the DNA binding domain of the androgen receptor in two families with Reifenstein syndrome
Other mutations strike the hormone-binding pocket of the receptor instead. One well-characterized case involved a single amino acid swap deep in the steroid-binding domain. At normal body temperature, the mutant receptor could still bind androgens and switch on target genes, though less efficiently than the normal version. But at slightly elevated temperatures, androgen binding fell off sharply, suggesting that the receptor was structurally fragile in a way that matters for tissues like the scrotum, which sit at temperatures close to or above core body temperature.3PubMed. A single amino acid substitution (gly743 –> val) in the steroid-binding domain of the human androgen receptor leads to Reifenstein syndrome
Not all mutations are easy to find. In one extensively studied Texas family whose members had been tracked since the 1970s, researchers spent years searching the coding regions of the AR gene without success. The culprit turned out to be a change buried deep within an intron, one of the non-coding stretches between functional gene segments. That variant created an abnormal splicing event, inserting extra nucleotides with a premature stop signal into the messenger RNA. The result was likely a reduction in the total amount of functional receptor protein the cells could make, rather than a receptor that worked incorrectly.4PubMed Central. Identification of the Underlying Androgen Receptor Defect in the Dallas Reifenstein Family That discovery is a reminder that standard genetic testing can miss the mutation if it only looks at coding sequences.
What the Body Looks Like When Androgen Signaling Is Only Partly Blocked
Because androgen receptors are scattered across nearly every tissue, partial insensitivity produces a constellation of features rather than one isolated problem. The severity depends on how much receptor function remains, and that varies with the specific mutation. At the milder end, an affected person might have a normally formed penis with just a slightly misplaced urethral opening and develop breast tissue at puberty. At the more severe end, the external genitalia can appear ambiguous at birth, with significant hypospadias, a bifid scrotum, and testes that have not fully descended.
Gynecomastia is one of the most consistent features and often the one that brings adolescents to clinical attention. The explanation involves the balance between androgens and estrogens. When cells cannot respond well to testosterone, the relative influence of estrogen on breast tissue goes unchecked. A hormonal study of two brothers with the Reifenstein phenotype found that their daily estradiol production was elevated, though not as high as in some other men with more severe androgen insensitivity.5PubMed. Estrogen and androgen production rates in two brothers with Reifenstein syndrome Higher estrogen activity against a backdrop of weakened androgen signaling pushes breast tissue to grow.
Fertility is generally impaired. Most affected individuals have low sperm counts or produce no sperm at all. The testes themselves are present and usually produce testosterone at normal or above-normal rates, but the feedback loop between the brain and the gonads is disrupted. Luteinizing hormone levels tend to run high because the hypothalamus and pituitary, sensing that androgen signaling is weak, keep trying to drive more testosterone production. This pattern of high LH with normal-to-high testosterone is actually one of the hormonal fingerprints clinicians look for during evaluation.
How Reifenstein Syndrome Is Diagnosed
Diagnosis can be straightforward when an infant is born with obviously ambiguous genitalia and chromosome testing reveals a 46,XY karyotype. It becomes trickier when the degree of undervirilization is mild and the child appears to be a typically developing male until puberty, when gynecomastia or incomplete virilization prompts investigation.
The hormonal workup typically shows elevated LH and normal-to-elevated testosterone. Those findings help distinguish PAIS from conditions where androgen production itself is the problem. Dihydrotestosterone levels and the enzyme that produces it in genital skin fibroblasts are usually normal, which separates the condition from 5-alpha reductase deficiency, a disorder that can look similar on physical exam.6PubMed Central. High dose androgen therapy in male pseudohermaphroditism due to 5 alpha-reductase deficiency and disorders of the androgen receptor
Androgen-binding studies on skin cells grown from a genital biopsy were once the gold standard. A clearly abnormal binding result pointed strongly toward an androgen receptor defect. But some mutations, particularly those in the DNA-binding domain rather than the hormone-binding domain, leave binding completely normal. In those cases, researchers found that the receptor grabbed onto androgens just fine but failed to activate genes properly once inside the nucleus.7PubMed Central. Point mutation in the DNA binding domain of the androgen receptor in two families with Reifenstein syndrome Genetic sequencing of the AR gene has largely replaced binding assays as the confirmatory step, though even sequencing can miss intronic variants if it is limited to exon-only panels, as the Dallas family’s decades-long diagnostic journey illustrates.
Telling It Apart From Similar Conditions
Several other conditions produce undervirilized genitalia in XY individuals, and getting the distinction right matters for treatment. In 5-alpha reductase deficiency, the body makes testosterone normally but cannot convert it efficiently to dihydrotestosterone, the hormone primarily responsible for external genital development before birth. The clinical overlap can be substantial: both conditions may present with hypospadias, a small phallus, and undescended testes. The differentiating clue is in the biochemistry. In 5-alpha reductase deficiency, the testosterone-to-dihydrotestosterone ratio is abnormally high and the enzyme activity in skin fibroblasts is low, while in PAIS both are normal.8PubMed Central. High dose androgen therapy in male pseudohermaphroditism due to 5 alpha-reductase deficiency and disorders of the androgen receptor
Complete androgen insensitivity syndrome (CAIS) sits at the other end of the same spectrum. In CAIS, androgen receptor function is entirely absent, and the individual typically develops a female external appearance despite having XY chromosomes and internal testes. There is no clinical overlap with Reifenstein syndrome in classic cases, but the boundary between severe PAIS and mild CAIS can blur when receptor function is almost but not quite zero. Genetic testing of the AR gene is the clearest way to resolve ambiguous cases.
Disorders of testosterone synthesis, such as 17-beta hydroxysteroid dehydrogenase deficiency, can also mimic PAIS. These involve low testosterone itself, which usually shows up as low or low-normal testosterone levels on blood testing rather than the elevated or normal levels seen in receptor-based conditions.
Managing Gynecomastia
Breast tissue growth is one of the most psychologically distressing features for individuals with PAIS who are raised male, and it tends to be resistant to medical treatments. A recent study examining gynecomastia management in boys with PAIS found that about seven in ten had either undergone surgical removal of breast tissue or were on a waiting list for the procedure, at a median age of 16. Roughly a third of those who had surgery had previously tried medications, with poor results. When clinicians rated how well each approach worked on a scale, surgery scored far higher than medical therapy.9The Journal of Clinical Endocrinology & Metabolism. Gynecomastia and Its Management In Boys With Partial Androgen Insensitivity Syndrome This is consistent with the underlying biology: the breast tissue has grown because androgen signaling cannot suppress estrogen’s effects, and no drug can fully compensate for a fundamentally impaired receptor.
Surgical outcomes are generally good in experienced hands, though recurrence is possible if residual glandular tissue is left behind. Timing is usually deferred until mid-adolescence, after breast development has plateaued, to reduce the chance of regrowth.
High-Dose Testosterone and Its Limits
A logical question is whether flooding the body with more androgen can overcome a partially defective receptor. The answer is: sometimes, partially, and it depends entirely on the specific mutation. In a study that gave high-dose testosterone to two patients with PAIS, both showed signs of increased androgen action, including better nitrogen retention, a rough marker of anabolic response. One patient also showed a rise in sebum production to normal levels, a skin response driven by androgens. But the second patient had no change in sebum, illustrating that two people with the “same” syndrome can respond very differently.10PubMed. Correlation of clinical, endocrine and molecular abnormalities with in vivo responses to high-dose testosterone in patients with partial androgen insensitivity syndrome
The practical takeaway is that a trial of testosterone can be worthwhile in adolescence or early adulthood, particularly for individuals hoping to improve virilization or muscle mass, but expectations need to be calibrated. If the mutation leaves the receptor severely impaired, no amount of extra hormone will force a normal response. And there is a catch: testosterone is also converted to estradiol in the body, so flooding the system with androgens can simultaneously raise estrogen levels and worsen gynecomastia. Clinicians sometimes combine testosterone with an aromatase inhibitor to blunt that conversion, though evidence for this strategy in PAIS specifically is limited.
Gender Identity and Psychological Wellbeing
One of the more fraught aspects of PAIS has been the historical practice of assigning sex at birth based on the appearance of the genitalia, which sometimes led to siblings with the same mutation being raised in different genders. A case report of three siblings with PAIS found that one, raised female, identified as female, while the other two, raised male, identified as male. None of the three reported gender dysphoria.11PubMed. Psychosexual outcomes in three siblings with partial androgen insensitivity syndrome: impact of nature versus nurture That finding is small in scale but aligns with a broader observation across differences of sex development: gender identity tends to align with the sex of rearing more often than not, though exceptions certainly occur and underscore the need for long-term follow-up.
The psychological burden of living with PAIS goes beyond gender identity. Repeated genital surgeries in childhood, pubertal development that does not match peers, infertility, and the need for lifelong medical follow-up all take a toll. Current consensus guidelines emphasize multidisciplinary care that includes psychological support from early childhood, transparent communication with the patient about their condition as they mature, and deferred irreversible surgical decisions whenever safety permits.
Gonadal Tumor Risk
A question that comes up for anyone with an androgen insensitivity diagnosis is whether the testes carry an increased risk of cancer. In complete androgen insensitivity syndrome, there is a recognized risk of gonadal tumors, which is one reason prophylactic removal of the testes is sometimes discussed. The picture in PAIS and Reifenstein syndrome is more reassuring. A review of neoplasia in conditions of abnormal sexual differentiation found that tumors occur in complete androgen insensitivity but rarely in those with incomplete forms such as Reifenstein syndrome or 5-alpha reductase deficiency.12Cancer Genetics and Cytogenetics. Abnormal sexual differentiation and neoplasia
That said, “rarely” is not “never,” and the data on long-term tumor risk in PAIS are thinner than anyone would like, partly because the condition is uncommon and partly because surveillance protocols have changed over the decades. Most current guidelines recommend keeping the testes in place if the individual is being raised male, since the gonads are the primary source of testosterone and whatever virilization it can achieve. Regular monitoring with physical examination and, in some protocols, periodic imaging or tumor markers, is considered a reasonable middle ground.
Bone Health in the Context of Partial Androgen Resistance
Both androgens and estrogens play important roles in building and maintaining bone density. In PAIS, the weakened androgen signal can translate into lower bone mineral density, particularly if the testes are removed and hormone replacement is suboptimal. Estrogen, which is partly derived from testosterone through aromatization, also contributes to bone health in XY individuals, so keeping the testes intact and maintaining adequate circulating hormone levels is doubly important. Bone density screening is typically included in the long-term follow-up plan, especially after puberty and into adulthood, to catch any decline early enough to intervene with supplemental hormones, weight-bearing exercise, or other measures.
Why Genetic Counseling Matters for Families
Because the AR gene sits on the X chromosome, Reifenstein syndrome follows an X-linked recessive inheritance pattern. A carrier mother with one normal and one mutated copy of the gene has a 50 percent chance of passing the mutation to each child. Sons who inherit it will be affected; daughters who inherit it will be carriers but phenotypically unaffected. Genetic counseling can map the mutation’s path through a family, identify carriers, and help with reproductive planning. Prenatal or preimplantation genetic testing is available for known AR mutations, though families vary in whether they pursue it. The counseling conversation also provides an opportunity to discuss the wide range of outcomes that a single mutation can produce, since even within the same family, affected individuals sometimes differ in the severity of their features.